PI(3)King the Right Target
MBC Patients, Living with MBC, Making Our Best MBC Life, Biomarker Testing, Patient Initiatives Our MBClife MBC Patients, Living with MBC, Making Our Best MBC Life, Biomarker Testing, Patient Initiatives Our MBClife

PI(3)King the Right Target

PI(3)King the right target after CDK4/6 inhibitors fail patients is an exciting area of research and FDA approval. Now that there are multiple options approved by the FDA and more to come, patients have more treatment choices. Join host Abigail Johnston as she interviews 2 patients who give us their perspective on these advances, as well as a doctor whose scientific research has led the way identifying PIK3CA mutations as a cancer genomic biomarker.

Read More